SCHEMBL26627232

SCHEMBL26627232

O=c1ccc2c(OCCCCOc3ccc(O)cc3)c3ccoc3cc2o1

nearest known ligand 0.79

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
KCNA3 P22001 20/20 0.79
KCNA5 P22460 15/20 0.79
KCNA4 P22459 2/20 0.78
KCNA1 Q09470 2/20 0.78
KCNN4 O15554 1/20 0.78
THRB P10828 1/20 0.78
KCNA2 P16389 1/20 0.78
KCNA6 P17658 1/20 0.78
KCNMA1 Q12791 1/20 0.78
KCNH2 Q12809 1/20 0.78
KCNN1 Q92952 1/20 0.78
KCNA7 Q96RP8 1/20 0.78
KCNN2 Q9H2S1 1/20 0.78

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2576615 0.88 KCNA3 (1.00) KCNA3KCNA5KCNA4KCNA1KCNN4
SCHEMBL2585968 0.88 KCNA3 (1.00) KCNA3KCNA5KCNA4KCNA1KCNN4
SCHEMBL2581117 0.88 KCNA3 (1.00) KCNA3KCNA5KCNA4KCNA1KCNN4
SCHEMBL2583852 0.88 KCNA3 (1.00) KCNA3KCNA5KCNA4KCNA1KCNN4
SCHEMBL2585454 0.88 KCNA3 (1.00) KCNA3KCNA5KCNA4KCNA1KCNN4
SCHEMBL29410610 0.88 KCNA3 (1.00) KCNA3KCNA5KCNA4KCNA1KCNN4
SCHEMBL2586446 0.87 KCNA3 (1.00) KCNA3KCNA5KCNA4KCNA1KCNN4
SCHEMBL2582554 0.87 KCNA3 (0.98) KCNA3KCNA5KCNA4KCNA1KCNN4
SCHEMBL2586261 0.87 KCNA3 (0.98) KCNA3KCNA5KCNA4KCNA1KCNN4
SCHEMBL2586620 0.87 KCNA3 (0.98) KCNA3KCNA5KCNA4KCNA1KCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289837-A1 MITOCHONDRIOTROPIC HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS UNIV LJUBLJANI (SI) 2025-09-18 US disclosed
EP-4511125-A1 MITOCHONDRIOTROPIC BENZAMIDE POTASSIUM CHANNEL K1.3 INHIBITORS Univerza V Ljubljani (SI) 2025-02-26 EP disclosed
WO-2023203185-A1 MITOCHONDRIOTROPIC BENZAMIDE POTASSIUM CHANNEL K V1.3 INHIBITORS UNIVERZA V LJUBLJANI (SI) 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289837-A1 MITOCHONDRIOTROPIC HETEROARYL BENZAMIDE POTASSIUM CHANNEL KV1.3 INHIBITORS KCNJ2, KCNN3, KCNA3 KCNA3 3/4885KCNA5 21/4885KCNA4 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.